FIELD: medicine.
SUBSTANCE: described is a method for producing an oligonucleotide vaccine against the SARS-Cov-2 virus, comprising a thiophosphate construct of an oligonucleotide vaccine of the La-S-so type containing an antigen-presenting portion and an adjuvant portion represented by CpG-islands within the construct, 57 nucleotides long Lasso-1 5'-CCCCGGGGGGCAGAGACAGAAGAAACAG
CAAACCCCCCGGGGGAACGCCAACGCCT-3'.
EFFECT: invention speeds up the process of producing oligonucleotide vaccines; according to calculations, the time for producing the oligonucleotide vaccine is halved compared to other available platforms.
1 cl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR SIMULATING INFLAMMATORY RESPONSE IN MICE | 2023 |
|
RU2823685C1 |
| COMBINED DRUG WITH ANTIVIRAL EFFECT AGAINST NEW SARS-COV-2 CORONAVIRUS | 2021 |
|
RU2746362C1 |
| WHOLE VIRION INACTIVATED VACCINE AGAINST SARS-Cov-2 INFECTION AND ITS USE | 2023 |
|
RU2809375C1 |
| RECOMBINANT VACCINE STRAIN FOR LIVE INTRANASAL VACCINE PROVIDING COMBINED PREVENTION OF INFLUENZA AND CORONAVIRUS INFECTIONS | 2022 |
|
RU2782531C1 |
| METHOD OF OBTAINING INACTIVATED VACCINE AGAINST COVID-19 AND VACCINE OBTAINED BY METHOD | 2023 |
|
RU2810740C1 |
| VACCINE COMPOSITION AGAINST COVID-19 | 2020 |
|
RU2743595C1 |
| PEPTIDE IMMUNOGENS AND VACCINE COMPOSITION AGAINST COVID-19 WITH THE USE OF PEPTIDE IMMUNOGENS | 2020 |
|
RU2743593C1 |
| PEPTIDE IMMUNOGENS USED AS COMPONENTS OF VACCINE COMPOSITION AGAINST COVID-19 | 2020 |
|
RU2743594C1 |
| PEPTIDE IMMUNOGENS AND A VACCINE COMPOSITION AGAINST CORONAVIRUS INFECTION COVID-19 USING PEPTIDE IMMUNOGENS | 2020 |
|
RU2738081C1 |
| RECOMBINANT INFLUENZA VIRUS INTENDED FOR THE PREVENTION OF COVID-19 AND INFLUENZA, METHOD OF ITS PRODUCTION AND USE | 2022 |
|
RU2802058C1 |
